Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"The successful completion of our manufacturing validation program is a significant operational milestone for OncoSil Medical. Through our strategic partnership with Cyclotek, we have established a scalable Australian manufacturing capability that combines the efficiency of an experienced manufacturing partner with ownership of our specialised production equipment and proprietary manufacturing process. This model strengthens our control over quality, supply and manufacturing capability while supporting improved margins and positioning the Company to meet growing global commercial demand.

 Importantly, completing manufacturing validation substantially de-risks a key component of our commercial strategy by demonstrating that we have a validated production capability ready to support future market demand, subject to regulatory approval. We look forward to commencing commercial production during the second half of calendar 2026 following the completion of the regulatory approval process."